NCT01417156View on ClinicalTrials.gov

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Pulmonary Fibrosis
Interventions
DRUG

Nintedanib

150 mg bid

DRUG

Pirfenidoneone

Existing treatment

Trial Locations (4)

Unknown

Boehringer Ingelheim Investigational Site, Himeji, Hyogo

Boehringer Ingelheim Investigational Site, Sakai, Osaka

Boehringer Ingelheim Investigational Site, Seto, Aichi

Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01417156 - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) | Biotech Hunter | Biotech Hunter